Lumito on BioStock’s list of the 10 strongest life science stocks 2022
BioStock has listed this year's ten strongest Swedish life science stocks and taken a closer look at some companies to see what's behind the share price increases. Lumito is ranked third on the list: "Lumito rises ahead of market launch High up on this year's winners list we also find diagnostics company Lumito, […]
Reflections from the Digital Pathology & AI Congress. Lumito – New kid in town
Lumito participated with a booth of our own at the Digital Pathology & AI Congress in London in early December. The congress was attended by over 440 delegates and was held at a conference hotel at Heathrow. The delegates, primarily from Western Europe, were specifically interested in the digitalization of pathology with both research and […]
Lumitos presentation at BioStock Life Science Summit
Lumito's CEO Mattias Lundin presented the company and the upcoming product launch to the public in the well-attended Auditorium at Medicon Village in Lund. After the presentation, there was opportunity for Q&As which included delayed launch, possibilities for multiplexing and analysis of more biomarkers as well as whether there are plans to launch the product […]
The scientific article “Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer” is now published in Cancer Immunology Research
The scientific article entitled "Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer" is now published in the scientific journal Cancer Immunology Research. The main objective of the journal is to publish the best new findings from leading experts in chemistry, biology and clinical science. The paper is written by Daniel […]
Lumito AB publishes Quarterly Report 3, 2022
Financial overview of the third quarter July 1 to September 30, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 815 (-6 073). Earnings per share before and after dilution amounted to SEK -0.04 (-0.07). Cash flow from operating activities after changes in working capital amounted to TSEK -9 […]
The pre-launch phase of SCIZYS by Lumito continues without interruption
The pre-launch phase, which started in Spring 2022, continues and is now intensified as planned. Lumito will be represented with its own stand at the Digital Pathology & AI Congress: Europe in London on December 7-8. The presence at the congress will be complemented by advertising and editorial in the international professional journal The Pathologist […]
The launch of SCIZYS by Lumito will be slightly delayed
As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch […]
Testing the Lumito scanner with the final product design
Lumito's research and development team has attended the operational testing of the company's scanner with the final product design at the Swedish partner, Optronics Partner pr. Since a few months ago Lumito is in the commercialization phase with production as an area of focus. The purpose of the briefing was to test all the scanner's functions […]
Lumito – Associated Member of PathLAKE and part of the Consortium’s highly valuable network
Lumito's application for Associate Membership of the PathLAKE Consortium has been approved. The PathLAKE Consortium is a network of leading NHS Trusts and UK universities who, in collaboration with industrial partners, are at the forefront of innovation in digital pathology. The Consortium's work includes AI-driven diagnostics to increase the efficiency and effectiveness of pathology reporting […]
Lumito publishes Quarterly Report 2, 2022
First half of the year 1 January–30 June 2022 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -13,610 (-13,444). Basic and diluted earnings per share amounted to SEK -0.09 (-0.15) Cash flow from operating activities after change in working capital amounted to KSEK -14,636 (-12,883). Cash and cash equivalents amounted […]
